LC
BIS icon

Lindbrook Capital’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Lindbrook Capital’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,125
Closed -$72K – 1745
2020
Q2 		$72K Buy
+1,125
New +$87.5K 0.02% 271

Other funds holding BIS

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Lindbrook Capital's BIS Position: Q3 2020 in Review

Lindbrook Capital sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q3 2020, closing a stake of 1,125 shares — an estimated $72K sold.

Lindbrook Capital first reported a position in BIS in Q2 2020 and held it in 1 quarter. The position peaked at $72K in Q2 2020. 7 funds tracked by Wall St. Rank hold BIS as of Q3 2020.

  • Lindbrook Capital reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q3 2020 after selling out during the quarter.
  • Lindbrook Capital sold 1,125 ProShares UltraShort NASDAQ Biotechnology shares in Q3 2020, an estimated $72K.
  • Lindbrook Capital first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2020 and held it in 1 quarter.
  • Lindbrook Capital's ProShares UltraShort NASDAQ Biotechnology position peaked at $72K in Q2 2020.
  • 7 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q3 2020.

Based on Lindbrook Capital's 13F filing for Q3 2020, filed 3 Nov 2020.